{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:46:05Z","timestamp":1789785965892,"version":"4.0.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2015,3,27]],"date-time":"2015-03-27T00:00:00Z","timestamp":1427414400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1007\/s00277-015-2324-0","type":"journal-article","created":{"date-parts":[[2015,3,26]],"date-time":"2015-03-26T11:33:30Z","timestamp":1427369610000},"page":"159-165","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":66,"title":["Management of chronic myeloid leukemia in blast crisis"],"prefix":"10.1007","volume":"94","author":[{"given":"S.","family":"Sau\u00dfele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,3,27]]},"reference":[{"key":"2324_CR1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/pds.1046","volume":"14","author":"S Tardieu","year":"2005","unstructured":"Tardieu S, Brun-Strang C, Berthaud P et al (2005) Management of chronic myeloid leukemia in France: a multicentered cross-sectional study on 538 patients. Pharmacoepidemiol Drug Saf 14:545\u2013553","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2324_CR2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/1756-0500-7-142","volume":"7","author":"MA Mottalib","year":"2014","unstructured":"Mottalib MA, Sultana TA, Khalil MI et al (2014) Phase distribution of chronic myeloid leukemia in Bangladesh. BMC Res Notes 7:142","journal-title":"BMC Res Notes"},{"key":"2324_CR3","first-page":"469","volume":"19","author":"R Ahmed","year":"2009","unstructured":"Ahmed R, Naqi N, Hussain I et al (2009) Presentating phases of chronic myeloid leukaemia. J Coll Phys Surg Pak 19:469\u2013472","journal-title":"J Coll Phys Surg Pak"},{"key":"2324_CR4","unstructured":"Lindoerfer D, Hoffmann VS, Rosti G et al (2014) The EUTOS population-based registry: evaluation of baseline characteristics and first treatment choices of 3045 newly diagnosed chronic myeloid leukemia (CML) patients from 20 European countries. Haematologica. epub ahead of print: Abstract"},{"key":"2324_CR5","unstructured":"Hochhaus A, Kim D-W, Shah NP et al (2013) Four-Year (Yr) Follow-Up Of Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP) Receiving Dasatinib Or Imatinib: Efficacy Based On Early Response. Blood. 122: Abstract 653"},{"key":"2324_CR6","first-page":"P275","volume":"99","author":"S Sau\u00dfele","year":"2014","unstructured":"Sau\u00dfele S, Kalmanti L, Lauseker M, Dietz C, Heinrich L, Schwerdtfeger R, Kolb HJ, Gratwohl A, Krause SW, Falge C, Dengler J, Kanz L, Stegelmann F, Pfreundschuh M, Spiekermann K, Buchert A, Neubauer A, Ehninger G, Hossfeld DK, Heimpel H, M\u00fcller MC, Fabarius A, Hochhaus A, Pfirrmann M, Hasford J, Hehlmann R (2014) Management and outcome of CML-blast crisis: results from the randomized CML study IV. Haematologica 99:P275","journal-title":"Haematologica"},{"key":"2324_CR7","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1182\/blood-2013-06-510396","volume":"123","author":"TP Hughes","year":"2013","unstructured":"Hughes TP, Saglio G, Kantarjian HM et al (2013) Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood 123:1353\u20131360","journal-title":"Blood"},{"key":"2324_CR8","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1182\/blood-2012-03-380147","volume":"120","author":"R Hehlmann","year":"2012","unstructured":"Hehlmann R (2012) How I treat CML blast crisis. Blood 120:737\u2013747","journal-title":"Blood"},{"key":"2324_CR9","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1182\/blood.V82.2.398.398","volume":"82","author":"R Hehlmann","year":"1993","unstructured":"Hehlmann R, Heimpel H, Hasford J et al (1993) Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: Prolongation of survival by hydroxyurea. Blood 82:398\u2013407","journal-title":"Blood"},{"key":"2324_CR10","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood.V84.12.4064.bloodjournal84124064","volume":"84","author":"R Hehlmann","year":"1994","unstructured":"Hehlmann R, Heimpel H, Hasford J et al (1994) Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML study group. Blood 84:4064\u20134077","journal-title":"Blood"},{"key":"2324_CR11","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/sj.leu.2403006","volume":"17","author":"R Hehlmann","year":"2003","unstructured":"Hehlmann R, Berger U, Pfirrmann M et al (2003) Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia 17:1529\u20131537","journal-title":"Leukemia"},{"key":"2324_CR12","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","volume":"29","author":"R Hehlmann","year":"2011","unstructured":"Hehlmann R, Lauseker M, Jung-Munkwitz S et al (2011) Tolerability-adapted imatinib 800\u00a0mg\/d versus 400\u00a0mg\/d versus 400\u00a0mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia. J Clin Oncol 29:1634\u20131642","journal-title":"J Clin Oncol"},{"key":"2324_CR13","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.2013.49.9020","volume":"32","author":"R Hehlmann","year":"2014","unstructured":"Hehlmann R, M\u00fcller MC, Lauseker M et al (2014) Deep molecular response (MR4.5) is reached by the majority of imatinib-treated patients, predicts survival, and is achieved faster by optimized high-dose imatinib\u2014results from the randomized CML-study IV. J Clin Oncol 32:415\u2013423","journal-title":"J Clin Oncol"},{"key":"2324_CR14","first-page":"477","volume":"2009","author":"TP Hughes","year":"2009","unstructured":"Hughes TP, Branford S (2009) Monitoring disease response to tyrosine kinase inhibitor therapy in CML. ASH Educ Program Book 2009:477\u2013487","journal-title":"ASH Educ Program Book"},{"key":"2324_CR15","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1182\/blood.V32.3.445.445","volume":"32","author":"A Karanas","year":"1968","unstructured":"Karanas A, Silver RT (1968) Characteristics of the terminal phase of chronic granulocytic leukemia. Blood 32:445\u2013459","journal-title":"Blood"},{"key":"2324_CR16","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/cncr.21756","volume":"106","author":"JE Cortes","year":"2006","unstructured":"Cortes JE, Talpaz M, O\u2019Brien S et al (2006) Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer 106:1306\u20131315","journal-title":"Cancer"},{"key":"2324_CR17","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.beha.2009.07.006","volume":"22","author":"RT Silver","year":"2009","unstructured":"Silver RT (2009) The blast phase of chronic myeloid leukaemia. Best Pract Res Clin Haematol 22:387\u2013394","journal-title":"Best Pract Res Clin Haematol"},{"key":"2324_CR18","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122:872\u2013884","journal-title":"Blood"},{"key":"2324_CR19","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","volume":"100","author":"JW Vardiman","year":"2002","unstructured":"Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292\u20132302","journal-title":"Blood"},{"key":"2324_CR20","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.3109\/10428194.2013.845883","volume":"55","author":"EJ Jabbour","year":"2014","unstructured":"Jabbour EJ, Hughes TP, Cortes JE et al (2014) Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leuk Lymphoma 55:1451\u20131462","journal-title":"Leuk Lymphoma"},{"key":"2324_CR21","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1182\/blood-2009-09-233981","volume":"116","author":"FE Nicolini","year":"2010","unstructured":"Nicolini FE, Morisset S, Hochhaus A et al (2010) The presence of the BCR ABL T315I mutation in chronic phase chronic myelogenous leukemia resistant to tyrosine kinase inhibitors profoundly compromises overall survival and progression free survival preliminary results of a matched pair analysts. Blood 116:1396\u20131397","journal-title":"Blood"},{"key":"2324_CR22","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/leu.2014.55","volume":"28","author":"R Kihara","year":"2014","unstructured":"Kihara R, Nagata Y, Kiyoi H et al (2014) Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients. Leukemia 28:1586\u20131595","journal-title":"Leukemia"},{"key":"2324_CR23","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","volume":"120","author":"PL Greenberg","year":"2012","unstructured":"Greenberg PL, Tuechler H, Schanz J et al (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120:2454\u20132465","journal-title":"Blood"},{"key":"2324_CR24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/1097-0142(197101)27:1<176::AID-CNCR2820270125>3.0.CO;2-B","volume":"27","author":"AA Sandberg","year":"1971","unstructured":"Sandberg AA, Hossfeld DK, Ezdinli EZ, Crosswhite LH (1971) Chromosomes and causation of human cancer and leukemia. VI. Blastic phase, cellular origin, and th Ph1 in CML. Cancer 27:176\u2013185","journal-title":"Cancer"},{"key":"2324_CR25","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","volume":"118","author":"A Fabarius","year":"2011","unstructured":"Fabarius A, Leitner A, Hochhaus A et al (2011) Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV. Blood 118:6760\u20136768","journal-title":"Blood"},{"key":"2324_CR26","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/leu.2010.298","volume":"25","author":"V Grossmann","year":"2011","unstructured":"Grossmann V, Kohlmann A, Zenger M et al (2011) A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9\u00a0% of cases. Leukemia 25:557\u2013560","journal-title":"Leukemia"},{"key":"2324_CR27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cancergencyto.2004.06.011","volume":"157","author":"U Bacher","year":"2005","unstructured":"Bacher U, Haferlach T, Hiddemann W et al (2005) Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression. Cancer Genet Cytogenet 157:53\u201361","journal-title":"Cancer Genet Cytogenet"},{"key":"2324_CR28","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000046636","volume":"107","author":"B Johansson","year":"2002","unstructured":"Johansson B, Fioretos T, Mitelman F (2002) Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 107:76\u201394","journal-title":"Acta Haematol"},{"key":"2324_CR29","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/asheducation-2007.1.384","volume":"2007","author":"JP Radich","year":"2007","unstructured":"Radich JP (2007) The biology of CML blast crisis. Hematol Am Soc Hematol Educ Program 2007:384\u2013391","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2324_CR30","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/nrc2147","volume":"7","author":"JV Melo","year":"2007","unstructured":"Melo JV, Barnes DJ (2007) Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 7:441\u2013453","journal-title":"Nat Rev Cancer"},{"key":"2324_CR31","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.1182\/blood-2003-12-4111","volume":"103","author":"B Calabretta","year":"2004","unstructured":"Calabretta B, Perrotti D (2004) The biology of CML blast crisis. Blood 103:4010\u20134022","journal-title":"Blood"},{"key":"2324_CR32","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood-2005-07-2815","volume":"108","author":"M Koptyra","year":"2006","unstructured":"Koptyra M, Falinski R, Nowicki MO et al (2006) BCR\/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance. Blood 108:319\u2013327","journal-title":"Blood"},{"key":"2324_CR33","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.1990.tb07832.x","volume":"76","author":"F Cervantes","year":"1990","unstructured":"Cervantes F, Rozman M, Rosell J et al (1990) A study of prognostic factors in blast crisis of Philadelphia chromosome-positive chronic myelogenous leukaemia. Br J Haematol 76:27\u201332","journal-title":"Br J Haematol"},{"key":"2324_CR34","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1182\/blood.V99.7.2304","volume":"99","author":"J Wadhwa","year":"2002","unstructured":"Wadhwa J, Szydlo RM, Apperley JF et al (2002) Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood 99:2304\u20132309","journal-title":"Blood"},{"key":"2324_CR35","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.13068","volume":"93","author":"F Palandri","year":"2008","unstructured":"Palandri F, Castagnetti F, Testoni N et al (2008) Chronic myeloid leukemia in blast crisis treated with imatinib 600\u00a0mg: outcome of the patients alive after a 6-year follow-up. Haematologica 93:1792\u20131796","journal-title":"Haematologica"},{"key":"2324_CR36","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3324\/haematol.2009.006999","volume":"94","author":"RT Silver","year":"2009","unstructured":"Silver RT, Cortes J, Waltzman R et al (2009) Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials. Haematologica 94:743\u2013744","journal-title":"Haematologica"},{"key":"2324_CR37","first-page":"1213","volume":"88","author":"A Sureda","year":"2003","unstructured":"Sureda A, Carrasco M, de Miguel M et al (2003) Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Haematologica 88:1213\u20131220","journal-title":"Haematologica"},{"key":"2324_CR38","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","volume":"99","author":"CL Sawyers","year":"2002","unstructured":"Sawyers CL, Hochhaus A, Feldman E et al (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99:3530\u20133539","journal-title":"Blood"},{"key":"2324_CR39","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood.V99.10.3547","volume":"99","author":"HM Kantarjian","year":"2002","unstructured":"Kantarjian HM, Cortes J, O\u2019Brien S et al (2002) Imatinib mesylate (STI571) therapy for Philadelphia chromosome\u2013positive chronic myelogenous leukemia in blast phase. Blood 99:3547\u20133553","journal-title":"Blood"},{"key":"2324_CR40","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0037-1963(01)90112-X","volume":"38","author":"B Druker","year":"2001","unstructured":"Druker B (2001) Signal transduction inhibition: results from phase I clinical trials in chronic myeloid leukemia. Semin Hematol 38:9\u201314","journal-title":"Semin Hematol"},{"key":"2324_CR41","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa055229","volume":"354","author":"M Talpaz","year":"2006","unstructured":"Talpaz M, Shah NP, Kantarjian H et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. NEngl J Med 354:2531\u20132541","journal-title":"N.Engl J Med"},{"key":"2324_CR42","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1038\/leu.2008.221","volume":"22","author":"J Cortes","year":"2008","unstructured":"Cortes J, Kim DW, Raffoux E et al (2008) Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia 22:2176\u20132183","journal-title":"Leukemia"},{"key":"2324_CR43","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1002\/cncr.25123","volume":"116","author":"G Saglio","year":"2010","unstructured":"Saglio G, Hochhaus A, Goh YT et al (2010) Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2\u00a0years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. Cancer 116:3852\u20133861","journal-title":"Cancer"},{"key":"2324_CR44","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Giles F, Wunderle L et al (2006) Nilotinib (AMN107), a novel, highly active, selective BCR-ABL tyrosine kinase inhibitor in patients with Philadelphia-Chromosome (Ph) positive chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) who are resistant to imatinib mesylate therapy. N.Engl.J Med. 2542-2551","DOI":"10.1056\/NEJMoa055104"},{"key":"2324_CR45","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1038\/leu.2011.355","volume":"26","author":"FJ Giles","year":"2012","unstructured":"Giles FJ, Kantarjian HM, le Coutre PD et al (2012) Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia 26:959\u2013962","journal-title":"Leukemia"},{"key":"2324_CR46","first-page":"6509","volume":"28","author":"C Gambacorti-Passerini","year":"2010","unstructured":"Gambacorti-Passerini C, Cortes JE, Khoury HJ et al (2010) Safety and efficacy of bosutinib in patients with AP and BP CML and ph\u2009+\u2009ALL following resistance\/intolerance to imatinib and other TKIs: update from study SKI-200. ASCO Meet Abstracts 28:6509","journal-title":"ASCO Meet Abstracts"},{"key":"2324_CR47","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J et al (2013) A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369:1783\u20131796","journal-title":"N Engl J Med"},{"key":"2324_CR48","unstructured":"Kim D-W, Pinilla-Ibarz J, le Coutre PD et al (2013) Ponatinib In Patients (pts) With Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph\u2009+\u2009ALL) Resistant Or Intolerant To Dasatinib Or Nilotinib, Or With The T315I BCR-ABL Mutation: 2-Year Follow-Up Of The PAC. 122: 650-650"},{"key":"2324_CR49","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3324\/haematol.2008.001214","volume":"93","author":"R Hehlmann","year":"2008","unstructured":"Hehlmann R, Saussele S (2008) Treatment of chronic myeloid leukemia in blast crisis. Haematol Hematol J 93:1765\u20131769","journal-title":"Haematol Hematol J"},{"key":"2324_CR50","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/cncr.22535","volume":"109","author":"S Fruehauf","year":"2007","unstructured":"Fruehauf S, Topaly J, Buss EC et al (2007) Imatinib combined with mitoxantrone\/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer 109:1543\u20131549","journal-title":"Cancer"},{"key":"2324_CR51","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cncr.22470","volume":"109","author":"Y Oki","year":"2007","unstructured":"Oki Y, Kantarjian HM, Gharibyan V et al (2007) Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer 109:899\u2013906","journal-title":"Cancer"},{"key":"2324_CR52","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/10428190601075973","volume":"48","author":"A Quintas-Cardama","year":"2007","unstructured":"Quintas-Cardama A, Kantarjian H, Garcia-Manero G et al (2007) A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma 48:283\u2013289","journal-title":"Leuk Lymphoma"},{"key":"2324_CR53","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/cncr.22901","volume":"110","author":"J Cortes","year":"2007","unstructured":"Cortes J, Jabbour E, Daley GQ et al (2007) Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer 110:1295\u20131302","journal-title":"Cancer"},{"key":"2324_CR54","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00277-010-0991-4","volume":"89","author":"B Fang","year":"2010","unstructured":"Fang B, Li N, Song Y et al (2010) Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with imatinib. Ann Hematol 89:1099\u20131105","journal-title":"Ann Hematol"},{"key":"2324_CR55","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/sj.leu.2404115","volume":"20","author":"D Rea","year":"2006","unstructured":"Rea D, Legros L, Raffoux E et al (2006) High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia 20:400\u2013403","journal-title":"Leukemia"},{"key":"2324_CR56","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.leukres.2010.11.004","volume":"35","author":"B Deau","year":"2011","unstructured":"Deau B, Nicolini FE, Guilhot J et al (2011) The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study). Leukemia Research 35:777\u2013782","journal-title":"Leukemia Research"},{"key":"2324_CR57","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3324\/haematol.2011.057513","volume":"97","author":"D Milojkovic","year":"2012","unstructured":"Milojkovic D, Ibrahim A, Reid A et al (2012) Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation. Haematol Hematol J 97:473\u2013474","journal-title":"Haematol Hematol J"},{"key":"2324_CR58","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/cncr.28433","volume":"120","author":"P Strati","year":"2014","unstructured":"Strati P, Kantarjian H, Thomas D et al (2014) HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia. Cancer 120:373\u2013380","journal-title":"Cancer"},{"key":"2324_CR59","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1016\/j.ejca.2013.07.147","volume":"49","author":"D Ghez","year":"2013","unstructured":"Ghez D, Micol JB, Pasquier F et al (2013) Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis. Eur J Cancer 49:3666\u20133670","journal-title":"Eur J Cancer"},{"key":"2324_CR60","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1002\/ajh.23624","volume":"89","author":"O Benjamini","year":"2014","unstructured":"Benjamini O, Dumlao TL, Kantarjian H et al (2014) Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol 89:282\u2013287","journal-title":"Am J Hematol"},{"key":"2324_CR61","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/bmt.2014.146","volume":"49","author":"H Jiang","year":"2014","unstructured":"Jiang H, Xu LP, Liu DH et al (2014) Allogeneic hematopoietic SCT in combination with tyrosine kinase inhibitor treatment compared with TKI treatment alone in CML blast crisis. Bone Marrow Transplant 49:1146","journal-title":"Bone Marrow Transplant"},{"key":"2324_CR62","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","volume":"23","author":"C Schmid","year":"2005","unstructured":"Schmid C, Schleuning M, Ledderose G et al (2005) Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol 23:5675\u20135687","journal-title":"J Clin Oncol"},{"key":"2324_CR63","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.hoc.2011.09.003","volume":"25","author":"N Jain","year":"2011","unstructured":"Jain N, van Besien K (2011) Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era. Hematol Oncol Clin North Am 25:1025\u20131048","journal-title":"Hematol Oncol Clin North Am"},{"key":"2324_CR64","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/bmt.2012.66","volume":"47","author":"JR Passweg","year":"2012","unstructured":"Passweg JR, Baldomero H, Gratwohl A et al (2012) The EBMT activity survey: 1990\u20132010. Bone Marrow Transplant 47:906\u2013923","journal-title":"Bone Marrow Transplant"},{"key":"2324_CR65","doi-asserted-by":"crossref","first-page":"4554","DOI":"10.1200\/JCO.2009.27.5867","volume":"28","author":"A Perotti","year":"2010","unstructured":"Perotti A, Locatelli A, Sessa C et al (2010) Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. J Clin Oncol 28:4554\u20134561","journal-title":"J Clin Oncol"},{"key":"2324_CR66","doi-asserted-by":"crossref","first-page":"6116","DOI":"10.1074\/jbc.M112.431312","volume":"288","author":"S Panjarian","year":"2013","unstructured":"Panjarian S, Iacob RE, Chen S et al (2013) Enhanced SH3\/linker interaction overcomes Abl kinase activation by gatekeeper and myristic acid binding pocket mutations and increases sensitivity to small molecule inhibitors. J Biol Chem 288:6116\u20136129","journal-title":"J Biol Chem"},{"key":"2324_CR67","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature08675","volume":"463","author":"J Zhang","year":"2010","unstructured":"Zhang J, Adrian FJ, Jahnke W et al (2010) Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature 463:501\u2013506","journal-title":"Nature"},{"key":"2324_CR68","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nchembio760","volume":"2","author":"FJ Adrian","year":"2006","unstructured":"Adrian FJ, Ding Q, Sim T et al (2006) Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol 2:95\u2013102","journal-title":"Nat Chem Biol"},{"key":"2324_CR69","doi-asserted-by":"crossref","first-page":"768","DOI":"10.2174\/15680096113139990086","volume":"13","author":"SA Held","year":"2013","unstructured":"Held SA, Heine A, Mayer KT et al (2013) Advances in immunotherapy of chronic myeloid leukemia CML. Curr Cancer Drug Targets 13:768\u2013774","journal-title":"Curr Cancer Drug Targets"},{"key":"2324_CR70","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/cam4.106","volume":"2","author":"DF McDermott","year":"2013","unstructured":"McDermott DF, Atkins MB (2013) PD-1 as a potential target in cancer therapy. Cancer Med 2:662\u2013673","journal-title":"Cancer Med"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2324-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-015-2324-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-015-2324-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T21:50:37Z","timestamp":1651614637000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-015-2324-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3,27]]},"references-count":70,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["2324"],"URL":"https:\/\/doi.org\/10.1007\/s00277-015-2324-0","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,27]]}}}